Healthcare Services

Acquired Immunodeficiency Syndrome (AIDS) Market Size Forecast To Achieve $43.28 Billion By 2030 With 5.1% CAGR

May 27, 2026May 26, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Value Outlook For The Acquired Immunodeficiency Syndrome (AIDS) Market Through 2030?

The market size for acquired immunodeficiency syndrome (AIDS) has shown substantial growth in recent years. It is projected to expand from $33.75 billion in 2025 to $35.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.3%. This historical growth can be attributed to several factors, including the high prevalence of HIV infections worldwide, increasing awareness and screening programs, government-funded HIV treatment initiatives, the availability of first-generation antiretroviral drugs, and a rising incidence of opportunistic infections.

The market size for acquired immunodeficiency syndrome (aids) is expected to demonstrate robust growth in the coming years. It is projected to expand to $43.28 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.1%. This anticipated expansion over the forecast period is driven by factors such as the development of advanced antiretroviral therapies, the widening reach of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) initiatives, advancements in HIV vaccine research, the adoption of digital health monitoring systems, and an increase in public-private partnerships aimed at HIV management. Noteworthy trends during this period include the rising acceptance of antiretroviral therapy (ART), increased usage of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), the broadening of HIV diagnostic and surveillance programs, an intensified focus on HIV vaccine research and development, and the integration of services across hospital and retail pharmacies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

Which Drivers Are Advancing The Acquired Immunodeficiency Syndrome (AIDS) Market Growth?

Rising instances of HIV infections are anticipated to drive the expansion of the acquired immunodeficiency syndrome (AIDS) market in the future. HIV infections describe a state caused by the human immunodeficiency virus (HIV), which targets the immune system, thus diminishing the body’s capacity to combat infections and illnesses. The growing prevalence of HIV infections stems from factors such as unprotected sexual contact with an infected individual, the shared use of needles or syringes, exposure to tainted blood products, engaging with multiple sexual partners, and having a compromised immune system or pre-existing sexually transmitted infections. The management of acquired immunodeficiency syndrome (AIDS) supports patients with HIV infection through encouraging prompt diagnosis, broadening availability of potent antiretroviral treatments, improving preventive measures, and reinforcing healthcare infrastructures, all of which contribute to more effective containment of the virus’s dissemination. As an illustration, in November 2024, figures released by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, indicated that 112,883 HIV diagnoses were registered in 2023 across 47 out of 53 regional countries, including 24,731 cases within the European Union/European Economic Area (EU/EEA). The collective crude rate of HIV diagnoses stood at 12.7 per 100,000 population, marking a 2.4% rise from the 12.4 per 100,000 rate noted in 2022. Consequently, the surge in HIV infections is a primary impetus for the acquired immunodeficiency syndrome (AIDS) market.

How Is The Acquired Immunodeficiency Syndrome (AIDS) Market Distributed Across Key Segments?

The acquired immunodeficiency syndrome (aids) market covered in this report is segmented –

1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2

2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis

3) By Route Of Administration: Oral, Parenteral

4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications

5) By Distribution Channel: Offline, Online

Subsegments:

1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management

2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections

Which Trends Are Influencing The Direction Of The Acquired Immunodeficiency Syndrome (AIDS) Market?

Leading companies in the acquired immunodeficiency syndrome (AIDS) market are concentrating on the development of innovative therapies, such as long-acting injectables. These advancements aim to enhance patient compliance, lessen the frequency of administration, and offer a more convenient alternative to daily oral antiretroviral treatments. Long-acting injectables are medications delivered through injection, formulated to slowly release their active ingredients over an extended duration, which allows for less frequent dosing when compared to traditional oral medications. For example, in January 2025, GSK plc, a UK-based pharmaceutical company, announced that the European Commission had granted approval for its long-acting injectable treatment, Vocabria (cabotegravir) combined with Rekambys (rilpivirine). This treatment is approved for use in adolescents aged 12 years and older who are living with HIV. It is administered via intramuscular injection, typically either every one or two months, depending on the particular treatment plan. The prolonged action of these injections has the potential to improve adherence rates among adolescents who encounter difficulties with daily pill regimens.

Which Key Players Are Active In The Acquired Immunodeficiency Syndrome (AIDS) Market?

Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Access The Complete Acquired Immunodeficiency Syndrome (AIDS) Market Report:

https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

Which Region Is The Primary Market For The Acquired Immunodeficiency Syndrome (AIDS) Market?

North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Acquired Immunodeficiency Syndrome (AIDS) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp

Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2026, By The Business Research Company

Acne Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Walking Aids Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/walking-aids-global-market-report

Immunoassay Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795